中国肝脏病杂志(电子版)
中國肝髒病雜誌(電子版)
중국간장병잡지(전자판)
CHINESE JOURNAL OF LIVER DISEASES(ELECTRONIC VERSION)
2014年
4期
39-41
,共3页
恩替卡韦%肝炎,乙型%肝硬化
恩替卡韋%肝炎,乙型%肝硬化
은체잡위%간염,을형%간경화
Entecavir%Hepatitis B%Liver cirrhosis
目的:观察加减平胃四逆方联合ETV治疗乙型肝炎失代偿期肝硬化的临床疗效。方法将50例乙型肝炎失代偿期肝硬化患者分为治疗组和对照组各25例,对照组给予综合治疗并口服ETV分散片0.5 mg/次,每日1次;治疗组在此基础上加服加减平胃四逆方,每日1剂,分两次服用。两组患者疗程均为24周。观察患者治疗前后肝功能、PTA、HBV DNA定量、Child-Pugh评分变化情况。结果治疗组在改善肝功能、PTA、降低Child-Pugh评分方面疗效显著优于对照组;在HBV DNA低于检测下限的比率方面,两组差异无统计学意义。结论加减平胃四逆方联合ETV治疗乙型肝炎失代偿期肝硬化在改善肝功能、PTA、降低Child-Pugh评分方面疗效确切。
目的:觀察加減平胃四逆方聯閤ETV治療乙型肝炎失代償期肝硬化的臨床療效。方法將50例乙型肝炎失代償期肝硬化患者分為治療組和對照組各25例,對照組給予綜閤治療併口服ETV分散片0.5 mg/次,每日1次;治療組在此基礎上加服加減平胃四逆方,每日1劑,分兩次服用。兩組患者療程均為24週。觀察患者治療前後肝功能、PTA、HBV DNA定量、Child-Pugh評分變化情況。結果治療組在改善肝功能、PTA、降低Child-Pugh評分方麵療效顯著優于對照組;在HBV DNA低于檢測下限的比率方麵,兩組差異無統計學意義。結論加減平胃四逆方聯閤ETV治療乙型肝炎失代償期肝硬化在改善肝功能、PTA、降低Child-Pugh評分方麵療效確切。
목적:관찰가감평위사역방연합ETV치료을형간염실대상기간경화적림상료효。방법장50례을형간염실대상기간경화환자분위치료조화대조조각25례,대조조급여종합치료병구복ETV분산편0.5 mg/차,매일1차;치료조재차기출상가복가감평위사역방,매일1제,분량차복용。량조환자료정균위24주。관찰환자치료전후간공능、PTA、HBV DNA정량、Child-Pugh평분변화정황。결과치료조재개선간공능、PTA、강저Child-Pugh평분방면료효현저우우대조조;재HBV DNA저우검측하한적비솔방면,량조차이무통계학의의。결론가감평위사역방연합ETV치료을형간염실대상기간경화재개선간공능、PTA、강저Child-Pugh평분방면료효학절。
Objective To investigate the effect of modified prescription of pingweisini combined with entecavir (ETV) on patients at decompensation stage of liver cirrhosis. Methods Total of 50 cases were randomly divided into control group and treatment group with 25 cases per group. The control group received comprehensive therapy and ETV 0.5 mg/d, once a day, while the treatment group was treated with ETV 0.5 mg/d, once a day and modiifed prescription of pingweisini twice a day for 24 weeks besides the comprehensive therapy. Liver function, prothrombin time activity (PTA), quantitative level of HBV DNA and Child-Pugh scale was were assessed before and after treatment. Results Compared with control group, the liver function, PTA was improved, score of Child-Pugh scale was decreased in treatment group;there is no signigicant difference in inhibiting HBV of both groups. conclusions Combined therapy of modiifed prescription of pingweisini and ETV on treatment of decompensation stage of hepatic cirrhosis, especially in improving liver function, prothrombin time activity (PTA) and inhibiting HBV, had curative effect.